Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our Phase I HER2 Breast Cancer Study. You can read more about the status and progress of the study and other key achievements in the quarter in our latest Appendix 4C and Quarterly Activity Report.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal